江中药业股份有限公司 第十届董事会第十一次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 江中药业股份有限公司（以下简称"公司"或"江中药业"）第十届董事会 第十一次会议于 2025 年 12 月 29 日在公司会议室以现场结合视频方式召开，会 议通知于 2025 年 12 月 24 日以书面形式发出，会议应到董事 11 人，实到董事 11 人。公司高级管理人员列席。本次会议召集召开符合《公司法》和《公司章 程》的有关规定。 会议由公司董事长刘为权先生主持，经与会董事充分研究和讨论，审议通 过以下议案： 一、关于聘任公司总经理的议案 表决情况：10 票同意，0 票反对，0 票弃权，1 票回避，通过本议案。 根据《公司法》《公司章程》等相关规定，结合公司经营管理需要，经公司 董事长提名、公司董事会提名委员会资格审查，董事会聘任徐永前先生为公司 总经理，任期与公司第十届董事会任期一致。 董事徐永前对本议案履行了回避表决程序。 证券代码：600750 证券简称：江中药业 公告编号：2025-067 具体内容详见公 ...

Group 1 - Jiangzhong Pharmaceutical (SH 600750) announced the convening of its 11th meeting of the 10th Board of Directors on December 29, 2025, to discuss the appointment of a new general manager [1] - For the first half of 2025, Jiangzhong Pharmaceutical's revenue composition was as follows: pharmaceutical industry accounted for 99.64%, liquor industry 0.25%, and other businesses 0.11% [1] - As of the report date, Jiangzhong Pharmaceutical's market capitalization was 15 billion yuan [1] Group 2 - A new type of chip has been developed in China, which bypasses the restrictions on lithography machines and supports AI training and embodied intelligence, capable of mass production using mature processes of 28 nanometers and above [1]

Summary of Conference Call on Traditional Chinese Medicine Industry Industry Overview - The conference call focuses on the Traditional Chinese Medicine (TCM) industry, specifically the pricing of medicinal materials and the over-the-counter (OTC) market dynamics [1][3]. Key Points and Arguments - **Price Decline of Medicinal Materials**: The price of natural cow bile has decreased from over 1.4 million yuan per kilogram to 1.1 million yuan, indicating weak demand impacting upstream production companies [1][3]. - **Performance of OTC Products**: Data from nearly 100,000 small and medium-sized chain pharmacies, representing 20% market share, shows that products related to cold relief, such as Lianhua Qingwen capsules and pediatric Chiqiao Qingre granules, performed well in November, expected to drive growth in Q4 and Q1 of the following year [1][3]. - **Stability in Orthopedic and Digestive Products**: Sales of orthopedic and digestive products, such as Lingzhi Pharmaceutical's hemorrhoid ointment and Yunnan Baiyao's plaster preparations, remain stable. Yunnan Baiyao's Qixue Kang has maintained high double-digit growth since Q4 2024 due to academic promotion in grassroots medical institutions and chain pharmacies [1][3]. - **Pressure on Qi and Blood Supplement Products**: Products like Mayinglong hemorrhoid ointment and some from Jianmin Group face growth pressure, but this is expected to ease by December this year and into next year [1][3]. - **Healthy Inventory and Cash Flow Management**: Companies with excellent inventory management and stable cash flow, such as Mayinglong and Jiangzhong, have maintained positive growth since January, with no historical burdens [1][3][4]. - **Long-term Price and Demand Relationship**: There is a close relationship between medicinal material prices and demand. The decline in prices since Q3 of last year reflects weakened demand in Q1 and Q2, which has begun to impact the upstream raw materials market [1][5]. Additional Important Insights - **Focus on Stable Companies**: Investors are advised to pay attention to companies with stable operations, good cash flow, and effective inventory control, as well as the stabilization of medicinal material prices and the recovery of the OTC market [2][4]. - **Monitoring Market Dynamics**: Continuous monitoring of medicinal material price stabilization and monthly OTC data recovery is crucial for assessing the overall recovery of the OTC market [5].

Core Viewpoint - The traditional education model in higher education institutions is struggling to meet the demands of high-quality economic and social development, leading to the adoption of industry-education integration as a key strategy to address talent supply and demand issues [1] Group 1: Optimizing Educational Content through Industry-Education Integration - The college focuses on industry transformation and upgrading by collaborating with industry enterprises and associations to develop and refine curriculum standards based on industry needs and technological advancements [2] - Project-based and modular courses are developed, incorporating real-world cases and technical challenges from enterprises into the teaching content, effectively linking classroom learning with industry [2] Group 2: Innovative Course Development - The college collaborates with Jiangxi Hebeikanghua Pharmaceutical Equipment Co., Ltd. to design a course on modern Chinese medicine pharmaceutical equipment, enhancing student engagement and understanding of industry trends [3] - A course on "Chinese Medicine Manufacturing and Green Intelligent Manufacturing" is offered, taught by experts from China Resources Jiangzhong Pharmaceutical Group, focusing on practical theories and technologies in green and intelligent manufacturing [3] Group 3: Hosting Industry-Education Integration Lectures - The college organizes forums like "Cloud Innovation and Intelligence Production," inviting industry representatives to facilitate dialogue between academia and industry, enhancing the integration of research and education [4] - Various themed forums are held to showcase talent needs in the pharmaceutical industry, providing insights into diverse career paths for students [4] Group 4: Transforming Educational Models - The college promotes project-based learning, case studies, and workshops, extending classroom learning into real-world settings to cultivate high-quality talent for the pharmaceutical industry [5] - Customized classes, such as the Hebeikanghua class, are established to closely align classroom learning with industry practices [5] Group 5: Comprehensive Practical Teaching Chain - The college constructs an integrated practical teaching chain that includes cognition, training, internships, and graduation projects, ensuring continuous and progressive practical education [6] - Emphasis is placed on academic competitions to enhance the effectiveness of industry-education collaboration, with students participating in competitions aimed at solving real technical challenges faced by enterprises [6] Group 6: Promoting Social Practice - The college organizes social practice teams to conduct market research in the pharmaceutical industry, gathering valuable insights for market analysis and report generation [6] - A focus on dual innovation education is maintained, with the establishment of a collaborative innovation and entrepreneurship practice base in the pharmaceutical sector [7] Group 7: Encouraging Entrepreneurial Initiatives - The college hosts "Maker Markets" to inspire entrepreneurial thinking among students, showcasing innovative products developed by students at various industry events [7]

近年来，中医药滋补养生市场持续扩容。其中，六味地黄类产品作为滋阴补肾的经典品类，市场需求潜 力巨大。与此同时，传统剂型正加速向更便捷、更适口的方向创新，膏滋、口服液等新剂型日益受到当 代快节奏生活人群的青睐。华润江中敏锐洞察这一趋势，将传承千年的经典名方与现代剂型创新相结 合，为滋阴补肾市场带来一款易于服用、方便携带、高效吸收的膏滋新品，满足现代消费者对高效、便 捷、品质滋补的新需求。 12月25日，华润江中旗下六味地黄膏在京东健康首发上线，消费者即日起登录京东APP搜索"江中六味 地黄膏"即可咨询与购买，开启轻松、便捷的滋补调理新体验。 作为国民信赖的健康品牌，华润江中始于1969年，是一家集医药研发、生产与销售于一体的国有大型企 业，旗下"江中"品牌价值超466亿元，已连续22年入选中国500最具价值品牌。其位于南昌的江中药谷制 造基地，是国家级绿色工厂与智能制造的典范。2023年，华润江中牵头获批"经典名方现代中药创制全 国重点实验室"，依托4个国家级及8个省部级研发平台，构建了从药材源头到产品出厂的全链条质量管 控体系，为六味地黄膏等产品的卓越品质保驾护航。 本次新品发布是双方深度合作的又一重要里程碑 ...

Group 1 - The core product launched by China Resources Jiangzhong is a new formulation of the classic "Liuwei Dihuang Wan," transitioning from pill to paste form, designed for modern fast-paced lifestyles [1] - The traditional Chinese medicine market for kidney tonics is projected to reach 48.73 billion yuan in 2024, with a year-on-year growth of 9.2%, indicating a significant consumer trend towards health products that are efficient and convenient [1] - The new product features a portable design with independent packaging, enhancing convenience for users while also focusing on taste by incorporating honey for a sweet and slightly sour flavor [1] Group 2 - A representative from China Resources Jiangzhong emphasized that this innovation reflects the company's commitment to providing convenient health solutions and its role as a leader in the inheritance and innovation of traditional Chinese medicine [2] - Alibaba Health stated its role as a launch platform for new specialty drugs, aiming to provide consumers with easy access to health products, with many regions offering same-day or next-day delivery for the new product [2]

Group 1 - The core viewpoint of the articles highlights the growing market for kidney-tonifying traditional Chinese medicine (TCM) products, driven by changing consumer habits and the need for convenient health solutions in fast-paced urban lifestyles [1][2] - The market size for kidney-tonifying TCM products is projected to reach 48.73 billion yuan in 2024, reflecting a year-on-year growth of 9.2%, and accounting for 12.6% of the overall TCM market [1] - The introduction of the "Liuwedi Huang Gao" by China Resources Jiangzhong represents an innovation in dosage form, transitioning from traditional pills to a convenient paste format, catering to the needs of modern professionals [1][2] Group 2 - The new product features a portable, individually packaged design that emphasizes convenience and taste, incorporating high-quality honey for a pleasant flavor experience [2] - The launch of "Liuwedi Huang Gao" on Alibaba Health aims to provide consumers with easy access to health products, with same-day or next-day delivery options available in various regions [2] - The initiative reflects the company's commitment to integrating traditional Chinese medicine into modern lifestyles while fulfilling the health needs of the public [2]

Group 1: Gold Market Outlook - The long-term price of gold is expected to rise due to persistent high U.S. fiscal deficits and ongoing de-dollarization trends, supported by global central bank purchases of gold [9][10] - Tactical timing for gold investments in 2026 should focus on U.S. Treasury yield trends and volatility, as changes in the U.S. interest rate cycle may increase gold price volatility [9][10] - The demand for gold has significantly increased since 2022, primarily driven by central bank purchases, with expectations for a rebound in ETF demand in 2025 [9][10] Group 2: Alibaba's Cloud Business - Alibaba is positioned as a leading cloud provider in China, with a comprehensive self-developed technology stack that includes chips, servers, and cloud computing operating systems [10][13] - The growth of AI cloud services is expected to continue, driven by easing upstream chip pressures and increasing AI penetration in the market [10][13] - Alibaba's revenue projections for FY2026-FY2028 are estimated at 1,038.6 billion, 1,143.4 billion, and 1,250.6 billion RMB, with adjusted net profits of 101.9 billion, 145.5 billion, and 183.6 billion RMB respectively [10][13] Group 3: Jiangzhong Pharmaceutical - Jiangzhong Pharmaceutical has diversified its business into OTC, prescription drugs, and health consumer products, enhancing its market presence [21] - The company is focusing on expanding its OTC market with strong brand products, aiming for stable growth in its gastrointestinal health segment [21] - Future revenue projections for Jiangzhong Pharmaceutical are 854 million, 939 million, and 1,051 million RMB for 2025-2027, with a target valuation indicating a 36% growth potential [21] Group 4: AI-Driven E-commerce Operations - The e-commerce operation sector is experiencing a resurgence due to increased demand for brand agency services on platforms like Tmall, aided by AI technologies [16][17] - The company is leveraging AI to enhance operational efficiency and expand its client base, which is expected to drive revenue growth [16][17] - Future profit projections for the company are 111 million, 146 million, and 181 million RMB for 2025-2027, with a focus on maintaining a competitive edge in the market [16][17] Group 5: Honor Technology - Honor Technology is strategically positioned in the smart glasses and solid-state battery sectors, with significant growth potential in AI visual inspection technology [14][15] - The company has established partnerships with major clients like Apple and Meta, enhancing its market position in the consumer electronics sector [14][15] - Future growth in the solid-state battery market is anticipated, with the company actively developing inspection equipment for this emerging technology [14][15]

Group 1: Gold Market Outlook - The long-term outlook for gold prices remains positive due to persistent high U.S. fiscal deficits and a long-term trend of de-dollarization, supported by global central bank purchases of gold [9][10] - In 2026, tactical timing for gold investments should focus on U.S. Treasury yield trends and volatility, as changes in the U.S. interest rate cycle may increase gold price volatility compared to 2025 [9][10] - The demand for gold has significantly increased since 2022, primarily driven by central bank purchases, with a notable rise in ETF demand expected in 2025 [9][10] Group 2: Alibaba's Cloud and AI Strategy - Alibaba is positioned as a leading cloud provider in China with a comprehensive self-developed technology stack, including chips, servers, and AI models, which supports its revenue growth and profit margins [10][13] - The domestic AI cloud market is expected to continue its upward trajectory, driven by easing upstream chip pressures and increasing AI penetration rates [10][13] - Alibaba's strategy includes capturing the consumer-facing AI market by integrating its services across various platforms, enhancing user engagement and data asset accumulation [10][13] Group 3: Rongqi Technology's Market Position - Rongqi Technology focuses on intelligent detection and assembly equipment, with significant growth in its consumer electronics and new energy sectors, particularly in smart glasses and solid-state batteries [14][15] - The company has established strong partnerships with major clients like Apple and Meta, positioning itself well in the AI glasses market, which is expected to see increased demand [14][15] - In the new energy sector, Rongqi is strategically positioned to provide inspection equipment for solid-state batteries, collaborating with leading battery manufacturers [14][15] Group 4: Yiwang Yichuang's E-commerce Operations - Yiwang Yichuang has a solid foundation in e-commerce operations, leveraging AI to enhance operational efficiency and expand its client base [16][17] - The company has seen a recovery in its performance due to strategic adjustments and AI integration, with a projected increase in net profit in the coming years [16][17] - The e-commerce agency sector is experiencing renewed interest, driven by increased demand for brand representation on platforms like Tmall [16][17] Group 5: Jiangzhong Pharmaceutical's Growth Strategy - Jiangzhong Pharmaceutical has diversified its business into OTC, prescription drugs, and health consumer products, enhancing its market presence and brand value [19][20] - The company is focusing on expanding its OTC market share with strong product lines and leveraging its brand strength to drive growth [19][20] - Future growth is anticipated in the health consumer products sector, supported by demographic trends and increasing health awareness [19][20] Group 6: Zhongfu Industrial's Financial Outlook - Zhongfu Industrial is expected to benefit from cost improvements and increased production capacity, leading to enhanced earnings potential [20][21] - The company has a robust dividend policy, indicating strong long-term investment value [20][21] - Projections for net profit growth in the coming years reflect the company's strategic positioning in the aluminum industry [20][21]

Investment Rating - The report initiates coverage with a "Buy" rating for Jiangzhong Pharmaceutical, indicating a potential upside of 36% based on a target market value of 214 billion yuan compared to the current market value of 157 billion yuan [7][8]. Core Insights - Jiangzhong Pharmaceutical is positioned as a leader in gastrointestinal health, with a diversified business model encompassing OTC, prescription drugs, and health consumer products. The company has successfully built a strong brand presence with its well-known trademarks "Jiangzhong" and "Chuyuan" [5][16]. - The company has a robust product portfolio, including major products in the OTC market such as the 1 billion yuan "Jiangzhong Digestive Tablets" and the 500 million yuan "Lactobacillus Tablets" [7][36]. - The financial outlook is positive, with projected net profits for 2025-2027 expected to grow at compound annual growth rates of 8.3%, 10.0%, and 11.9%, respectively [6][8]. Summary by Sections Company Overview - Jiangzhong Pharmaceutical was established in 1969 and became publicly listed in 1998. The company has undergone significant restructuring and acquisitions, including the purchase of Jisheng Pharmaceutical and Sanghai Pharmaceutical, to enhance its market position [5][16]. - The company has a stable shareholding structure, with China Resources Group as the largest shareholder, which strengthens its operational capabilities and risk management [18][19]. Financial Data and Profit Forecast - The total revenue for 2024 is projected at 4.435 billion yuan, with a slight decline expected in 2025 before a recovery in subsequent years, reaching 5.089 billion yuan by 2027 [6]. - The gross profit margin is expected to remain stable around 65%, with the OTC segment showing a slight increase in profitability due to product mix optimization [26]. Investment Highlights - The company is focusing on expanding its OTC market presence by leveraging its strong brand and developing new product categories. The gastrointestinal product line is expected to maintain stable growth, while the health consumer products segment is anticipated to benefit from demographic trends such as aging populations [7][32]. - Jiangzhong Pharmaceutical's prescription drug segment is also expected to grow as the company continues to enhance its product offerings through acquisitions and strategic partnerships [7][32]. Market Position and Competitive Landscape - The company has maintained a leading market share in the OTC segment, particularly with its flagship product, the Jiangzhong Digestive Tablets, which ranked second in sales among digestive system medications in urban pharmacies [38][44]. - The competitive landscape for gastrointestinal products is fragmented, but Jiangzhong Pharmaceutical's brand strength allows it to maintain a dominant position [42][44].